Related Experiment Video
Updated: Feb 7, 2026

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
Published on: August 16, 2021
Left ventricular assist device implantation improves glycaemic control: a systematic review and meta-analysis
Nirav Patel1, Jason A Gluck1, Joseph Radojevic1
1Center for Advanced Heart Failure & Pulmonary Vascular Disease, Department of Cardiology, Hartford Hospital, Hartford, CT, USA.
Insights
Left ventricular assist device (LVAD) implantation significantly improves diabetes mellitus (DM) control in advanced heart failure (HF) patients. This meta-analysis found lower HbA1c, fasting glucose, and insulin needs after LVAD implantation.
Area of Science:
- Cardiology
- Endocrinology
- Medical Devices
Background:
- Heart failure (HF) and diabetes mellitus (DM) frequently coexist, with a bidirectional relationship.
- Advanced HF often leads to poorer glycemic control.
- Left ventricular assist device (LVAD) implantation is a treatment for advanced HF.
Purpose of the Study:
- To investigate the impact of LVAD implantation on diabetes mellitus (DM) control markers.
- To analyze changes in glycosylated hemoglobin A1c (HbA1c), fasting glucose, and insulin requirements post-LVAD.
Main Methods:
- Systematic literature search of MEDLINE and Cochrane databases up to October 2017.
- Inclusion of 13 studies with 820 participants with advanced HF who received LVAD.
- Pooled analysis using a Hartung-Knapp random-effects model to determine mean differences (MD) and 95% confidence intervals (CI).
Main Results:
- LVAD implantation was associated with a significant reduction in HbA1c by 1.23% (95% CI -1.49 to -0.98).
- Significant decreases were observed in fasting plasma glucose (-24.4 mg/dL) and daily insulin requirements (-18.8 units).
- Serum creatinine levels also decreased, while body mass index (BMI) showed no significant change.
Conclusions:
- LVAD implantation leads to significant improvements in glycemic control for advanced heart failure patients.
- Key markers such as HbA1c, fasting plasma glucose, and insulin needs are favorably affected.
- LVAD therapy offers a potential benefit for managing comorbid diabetes in advanced HF.
Aims:
Heart failure (HF) and diabetes mellitus (DM) often coexist and have bidirectional association. Advanced HF is associated with worsened glycaemic control. This meta-analysis investigated the effects of left ventricular assist device (LVAD) implantation on markers of DM control.
Methods And Results:
We performed a systematic search of MEDLINE and Cochrane through October 2017 to identify studies evaluating advanced HF patients who had received an LVAD and reported markers of glycaemic control. The primary outcome was glycosylated haemoglobin A1c (HbA1c), and the secondary outcomes included fasting glucose, daily insulin requirements, and body mass index (BMI). Outcomes were pooled using a Hartung-Knapp random-effects model producing a mean difference (MD) and 95% confidence interval (CI). Thirteen studies, including 820 participants, were included. HbA1c was 1.23% lower following LVAD implantation (95% CI -1.49 to -0.98). Greater HbA1c reductions were seen with higher pre-LVAD values. Similarly, fasting plasma glucose (-24.4 mg/dL, 95% CI -33.4 to -15.5), daily insulin requirements (-18.8 units, 95% CI -28.8 to -8.7), and serum creatinine levels (MD -0.20, 95% CI -0.35 to -0.06) were significantly lower than pre-LVAD levels. We saw no difference in BMI (MD 0.09, 95% CI -1.24 to 1.42).
Conclusions:
LVAD implantation was associated with significant improvement in HbA1c, fasting plasma glucose, and daily insulin need in advanced HF patients.
Related Concept Videos
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Random and Systematic Errors
Directing Effect of Substituents: meta-Directing Groups
Systematic Sampling Method
Systematic sampling is one of the simplest methods...
Propagation of Uncertainty from Systematic Error

